<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36341457</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Saliva antibody-fingerprint of reactivated latent viruses after mild/asymptomatic COVID-19 is unique in patients with myalgic-encephalomyelitis/chronic fatigue syndrome.</ArticleTitle><Pagination><StartPage>949787</StartPage><MedlinePgn>949787</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">949787</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.949787</ELocationID><Abstract><AbstractText Label="BACKGROUND">Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic disease considered to be triggered by viral infections in a majority of cases. Symptoms overlap largely with those of post-acute sequelae of COVID-19/long-COVID implying common pathogenetic mechanisms. SARS-CoV-2 infection is risk factor for sustained latent virus reactivation that may account for the symptoms of post-viral fatigue syndromes. The aim of this study was first to investigate whether patients with ME/CFS and healthy donors (HDs) differed in their antibody response to mild/asymptomatic SARS-CoV-2 infection. Secondly, to analyze whether COVID-19 imposes latent virus reactivation in the cohorts.</AbstractText><AbstractText Label="METHODS">Anti-SARS-CoV-2 antibodies were analyzed in plasma and saliva from non-vaccinated ME/CFS (n=95) and HDs (n=110) using soluble multiplex immunoassay. Reactivation of human herpesviruses 1-6 (HSV1, HSV2, VZV, EBV, CMV, HHV6), and human endogenous retrovirus K (HERV-K) was detected by anti-viral antibody fingerprints in saliva.</AbstractText><AbstractText Label="RESULTS">At 3-6 months after mild/asymptomatic SARS-CoV-2 infection, virus-specific antibodies in saliva were substantially induced signifying a strong reactivation of latent viruses (EBV, HHV6 and HERV-K) in both cohorts. In patients with ME/CFS, antibody responses were significantly stronger, in particular EBV-encoded nuclear antigen-1 (EBNA1) IgG were elevated in patients with ME/CFS, but not in HDs. EBV-VCA IgG was also elevated at baseline prior to SARS-infection in patients compared to HDs.</AbstractText><AbstractText Label="CONCLUSION">Our results denote an altered and chronically aroused anti-viral profile against latent viruses in ME/CFS. SARS-CoV-2 infection even in its mild/asymptomatic form is a potent trigger for reactivation of latent herpesviruses (EBV, HHV6) and endogenous retroviruses (HERV-K), as detected by antibody fingerprints locally in the oral mucosa (saliva samples). This has not been shown before because the antibody elevation is not detected systemically in the circulation/plasma.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Apostolou, Rizwan, Moustardas, Sj&#xf6;gren, Bertilson, Brag&#xe9;e, Polo and Ros&#xe9;n.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Apostolou</LastName><ForeName>Eirini</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Cell Biology, Department of Biomedical and Clinical Sciences, Link&#xf6;ping University, Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizwan</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Cell Biology, Department of Biomedical and Clinical Sciences, Link&#xf6;ping University, Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moustardas</LastName><ForeName>Petros</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Cell Biology, Department of Biomedical and Clinical Sciences, Link&#xf6;ping University, Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sj&#xf6;gren</LastName><ForeName>Per</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Family Medicine and Primary Care, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ME-center, Brag&#xe9;e Clinics, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertilson</LastName><ForeName>Bo Christer</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Division of Family Medicine and Primary Care, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ME-center, Brag&#xe9;e Clinics, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brag&#xe9;e</LastName><ForeName>Bj&#xf6;rn</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Family Medicine and Primary Care, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ME-center, Brag&#xe9;e Clinics, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polo</LastName><ForeName>Olli</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>ME-center, Brag&#xe9;e Clinics, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ros&#xe9;n</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cell Biology, Department of Biomedical and Clinical Sciences, Link&#xf6;ping University, Link&#xf6;ping, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007071">Immunoglobulin A, Secretory</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015673" MajorTopicYN="Y">Fatigue Syndrome, Chronic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012463" MajorTopicYN="N">Saliva</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015654" MajorTopicYN="Y">Herpesvirus 6, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020077" MajorTopicYN="Y">Endogenous Retroviruses</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007071" MajorTopicYN="N">Immunoglobulin A, Secretory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">EBV</Keyword><Keyword MajorTopicYN="N">HERV</Keyword><Keyword MajorTopicYN="N">HHV6A</Keyword><Keyword MajorTopicYN="N">ME/CFS</Keyword><Keyword MajorTopicYN="N">herpesvirus reactivation</Keyword><Keyword MajorTopicYN="N">latent virus</Keyword><Keyword MajorTopicYN="N">myalgic encephalomyelitis/chronic fatigue syndrome</Keyword></KeywordList><CoiStatement>PS, BCB, BB, and OP declare disclosure of interest as having income from Brag&#xe9;e Clinics, and BB being a partial owner. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>7</Day><Hour>5</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36341457</ArticleId><ArticleId IdType="pmc">PMC9630598</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.949787</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, et al. . Myalgic encephalomyelitis: International consensus criteria. J Intern Med (2011) 270:327&#x2013;38. doi:&#xa0;10.1111/j.1365-2796.2011.02428.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2011.02428.x</ArticleId><ArticleId IdType="pmc">PMC3427890</ArticleId><ArticleId IdType="pubmed">21777306</ArticleId></ArticleIdList></Reference><Reference><Citation>Carruthers BM. Definitions and aetiology of myalgic encephalomyelitis: How the Canadian consensus clinical definition of myalgic encephalomyelitis works. J Clin Pathol (2007) 60:117&#x2013;9. doi:&#xa0;10.1136/jcp.2006.042754</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jcp.2006.042754</ArticleId><ArticleId IdType="pmc">PMC1860613</ArticleId><ArticleId IdType="pubmed">16935963</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Gough J, Christmas D, Mattey DL, Richards SC, Main J, et al. . Microbial infections in eight genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis. J Clin Pathol (2010) 63:156&#x2013;64. doi:&#xa0;10.1136/jcp.2009.072561</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jcp.2009.072561</ArticleId><ArticleId IdType="pmc">PMC2921262</ArticleId><ArticleId IdType="pubmed">19955554</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickie I, Davenport T, Wakefield D, Vollmer-Conna U, Cameron B, Vernon SD, et al. . Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. Bmj (2006) 333:575. doi:&#xa0;10.1136/bmj.38933.585764.AE</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.38933.585764.AE</ArticleId><ArticleId IdType="pmc">PMC1569956</ArticleId><ArticleId IdType="pubmed">16950834</ArticleId></ArticleIdList></Reference><Reference><Citation>Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurol (2011) 11:37&#x2013;43. doi:&#xa0;10.1186/1471-2377-11-37</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-11-37</ArticleId><ArticleId IdType="pmc">PMC3071317</ArticleId><ArticleId IdType="pubmed">21435231</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg J, Gottfries CG, Elfaitouri A, Rizwan M, Ros&#xe9;n A. Infection elicited autoimmunity and myalgic Encephalomyelitis/Chronic fatigue syndrome: An explanatory model. Front Immunol (2018) 9:229. doi:&#xa0;10.3389/fimmu.2018.00229</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00229</ArticleId><ArticleId IdType="pmc">PMC5818468</ArticleId><ArticleId IdType="pubmed">29497420</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff AL, Bateman L. Will COVID-19 lead to myalgic Encephalomyelitis/Chronic fatigue syndrome? Front Med (Lausanne) (2020) 7:606824. doi:&#xa0;10.3389/fmed.2020.606824</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.606824</ArticleId><ArticleId IdType="pmc">PMC7848220</ArticleId><ArticleId IdType="pubmed">33537329</ArticleId></ArticleIdList></Reference><Reference><Citation>Poenaru S, Abdallah SJ, Corrales-Medina V, Cowan J. COVID-19 and post-infectious myalgic encephalomyelitis/chronic fatigue syndrome: A narrative review. Ther Adv Infect Dis (2021) 8:20499361211009385. doi:&#xa0;10.1177/20499361211009385</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20499361211009385</ArticleId><ArticleId IdType="pmc">PMC8060761</ArticleId><ArticleId IdType="pubmed">33959278</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff AL, Lipkin WI. Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome. Trends Mol Med (2021) 27:895&#x2013;906. doi:&#xa0;10.1016/j.molmed.2021.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2021.06.002</ArticleId><ArticleId IdType="pmc">PMC8180841</ArticleId><ArticleId IdType="pubmed">34175230</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh KK, Chaubey G, Chen JY, Suravajhala P. Decoding SARS-CoV-2 hijacking of host mitochondria in COVID-19 pathogenesis. Am J Physiol Cell Physiol (2020) 319:C258&#x2013;c67. doi:&#xa0;10.1152/ajpcell.00224.2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00224.2020</ArticleId><ArticleId IdType="pmc">PMC7381712</ArticleId><ArticleId IdType="pubmed">32510973</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang LW, Shen H, Nobre L, Ersing I, Paulo JA, Trudeau S, et al. . Epstein-Barr-Virus-Induced one-carbon metabolism drives b cell transformation. Cell Metab (2019) 30:539&#x2013;55 e11. doi:&#xa0;10.1016/j.cmet.2019.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2019.06.003</ArticleId><ArticleId IdType="pmc">PMC6720460</ArticleId><ArticleId IdType="pubmed">31257153</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiner P, Harrer T, Scheibenbogen C, Lamer S, Schlosser A, Naviaux RK, et al. . Human herpesvirus-6 reactivation, mitochondrial fragmentation, and the coordination of antiviral and metabolic phenotypes in myalgic Encephalomyelitis/Chronic fatigue syndrome. Immunohorizons (2020) 4:201&#x2013;15. doi:&#xa0;10.4049/immunohorizons.2000006</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/immunohorizons.2000006</ArticleId><ArticleId IdType="pubmed">32327453</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciccarese G, Parodi A, Drago F. SARS-CoV-2 as possible inducer of viral reactivations. Dermatol Ther (2020) 33:e13878. doi:&#xa0;10.1111/dth.13878</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dth.13878</ArticleId><ArticleId IdType="pmc">PMC7323010</ArticleId><ArticleId IdType="pubmed">32558172</ArticleId></ArticleIdList></Reference><Reference><Citation>Honore PM, Barreto Gutierrez L, Kugener L, Redant S, Attou R, Gallerani A, et al. . SARS-CoV-2 infection as a risk factor for herpesviridae reactivation: consider the potential influence of corticosteroid therapy. Crit Care (2020) 24:623&#x2013;4. doi:&#xa0;10.1186/s13054-020-03349-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03349-9</ArticleId><ArticleId IdType="pmc">PMC7581305</ArticleId><ArticleId IdType="pubmed">33092622</ArticleId></ArticleIdList></Reference><Reference><Citation>Maldonado MD, Romero-Aibar J, P&#xe9;rez-San-Gregorio MA. COVID-19 pandemic as a risk factor for the reactivation of herpes viruses. Epidemiol Infect (2021) 149:e145. doi:&#xa0;10.1017/s0950268821001333</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/s0950268821001333</ArticleId><ArticleId IdType="pmc">PMC8245334</ArticleId><ArticleId IdType="pubmed">34130765</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Balc'h P, Pinceaux K, Pronier C, Seguin P, Tadi&#xe9; JM, Reizine F. Herpes simplex virus and cytomegalovirus reactivations among severe COVID-19 patients. Crit Care (2020) 24:530. doi:&#xa0;10.1186/s13054-020-03252-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03252-3</ArticleId><ArticleId IdType="pmc">PMC7453668</ArticleId><ArticleId IdType="pubmed">32859241</ArticleId></ArticleIdList></Reference><Reference><Citation>Vigon L, Garcia-Perez J, Rodriguez-Mora S, Torres M, Mateos E, Castillo de la Osa M, et al. . Impaired antibody-dependent cellular cytotoxicity in a Spanish cohort of patients with COVID-19 admitted to the ICU. Front Immunol (2021) 12:742631. doi:&#xa0;10.3389/fimmu.2021.742631</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.742631</ArticleId><ArticleId IdType="pmc">PMC8488389</ArticleId><ArticleId IdType="pubmed">34616404</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le J, Hippchen T, Schnitzler P, Gsenger J, Giese T, Merle U. High rate of HSV-1 reactivation in invasively ventilated COVID-19 patients: Immunological findings. PloS One (2021) 16:e0254129. doi:&#xa0;10.1371/journal.pone.0254129</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0254129</ArticleId><ArticleId IdType="pmc">PMC8248692</ArticleId><ArticleId IdType="pubmed">34197543</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens (2021) 10:763. doi:&#xa0;10.3390/pathogens10060763</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10060763</ArticleId><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitsou K, Kotanidou A, Paraskevis D, Karamitros T, Katzourakis A, Tedder R, et al. . Upregulation of human endogenous retroviruses in bronchoalveolar lavage fluid of COVID-19 patients. Microbiol Spectr (2021) 9:e0126021. doi:&#xa0;10.1128/Spectrum.01260-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/Spectrum.01260-21</ArticleId><ArticleId IdType="pmc">PMC8510252</ArticleId><ArticleId IdType="pubmed">34612698</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassiotis G, Stoye JP. Immune responses to endogenous retroelements: taking the bad with the good. Nat Rev Immunol (2016) 16:207&#x2013;19. doi:&#xa0;10.1038/nri.2016.27</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2016.27</ArticleId><ArticleId IdType="pubmed">27026073</ArticleId></ArticleIdList></Reference><Reference><Citation>Young GR, Mavrommatis B, Kassiotis G. Microarray analysis reveals global modulation of endogenous retroelement transcription by microbes. Retrovirology (2014) 11:59. doi:&#xa0;10.1186/1742-4690-11-59</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-4690-11-59</ArticleId><ArticleId IdType="pmc">PMC4222864</ArticleId><ArticleId IdType="pubmed">25063042</ArticleId></ArticleIdList></Reference><Reference><Citation>Shikova E, Reshkova V, Kumanova &#x410;, Raleva S, Alexandrova D, Capo N, et al. . Cytomegalovirus, Epstein-Barr virus, and human herpesvirus-6 infections in patients with myalgic &#x435;ncephalomyelitis/chronic fatigue syndrome. J Med Virol (2020) 92:3682&#x2013;8. doi:&#xa0;10.1002/jmv.25744</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25744</ArticleId><ArticleId IdType="pmc">PMC7687071</ArticleId><ArticleId IdType="pubmed">32129496</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Neal AJ, Glass KA, Emig CJ, Vitug AA, Henry SJ, Shungu DC, et al. . Survey of anti-pathogen antibody levels in myalgic Encephalomyelitis/Chronic fatigue syndrome. Proteomes (2022) 10:21. doi:&#xa0;10.3390/proteomes10020021</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/proteomes10020021</ArticleId><ArticleId IdType="pmc">PMC9228258</ArticleId><ArticleId IdType="pubmed">35736801</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg J, Rizwan M, B&#xf6;hlin-Wiener A, Elfaitouri A, Julin P, Zachrisson O, et al. . Antibodies to human herpesviruses in myalgic Encephalomyelitis/Chronic fatigue syndrome patients. Front Immunol (2019) 10:1946. doi:&#xa0;10.3389/fimmu.2019.01946</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01946</ArticleId><ArticleId IdType="pmc">PMC6702656</ArticleId><ArticleId IdType="pubmed">31475007</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JS, Lacerda EM, Nacul L, Kingdon CC, Norris J, O'Boyle S, et al. . Salivary DNA loads for human herpesviruses 6 and 7 are correlated with disease phenotype in myalgic Encephalomyelitis/Chronic fatigue syndrome. Front Med (Lausanne) (2021) 8:656692. doi:&#xa0;10.3389/fmed.2021.656692</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.656692</ArticleId><ArticleId IdType="pmc">PMC8378328</ArticleId><ArticleId IdType="pubmed">34422848</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Tan Y, Ling Y, Lu G, Liu F, Yi Z, et al. . Viral and host factors related to the clinical outcome of COVID-19. Nature (2020) 583:437&#x2013;40. doi:&#xa0;10.1038/s41586-020-2355-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2355-0</ArticleId><ArticleId IdType="pubmed">32434211</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultze JL, Aschenbrenner AC. COVID-19 and the human innate immune system. Cell (2021) 184:1671&#x2013;92. doi:&#xa0;10.1016/j.cell.2021.02.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.02.029</ArticleId><ArticleId IdType="pmc">PMC7885626</ArticleId><ArticleId IdType="pubmed">33743212</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Q. Global percentage of asymptomatic SARS-CoV-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis: A systematic review and meta-analysis. JAMA Netw Open (2021) 4:e2137257. doi:&#xa0;10.1001/jamanetworkopen.2021.37257</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.37257</ArticleId><ArticleId IdType="pmc">PMC8672238</ArticleId><ArticleId IdType="pubmed">34905008</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobano C, Alonso S, Vidal M, Jimenez A, Rubio R, Santano R, et al. . Multiplex antibody analysis of IgM, IgA and IgG to SARS-CoV-2 in saliva and serum from infected children and their close contacts. Front Immunol (2022) 13:751705. doi:&#xa0;10.3389/fimmu.2022.751705</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.751705</ArticleId><ArticleId IdType="pmc">PMC8828491</ArticleId><ArticleId IdType="pubmed">35154094</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M, Worlock KB, Huang N, Lindeboom RGH, Butler CR, Kumasaka N, et al. . Local and systemic responses to SARS-CoV-2 infection in children and adults. Nature (2022) 602:321&#x2013;7. doi:&#xa0;10.1038/s41586-021-04345-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04345-x</ArticleId><ArticleId IdType="pmc">PMC8828466</ArticleId><ArticleId IdType="pubmed">34937051</ArticleId></ArticleIdList></Reference><Reference><Citation>Camell CD, Yousefzadeh MJ, Zhu Y, Langhi Prata LGP, Huggins MA, Pierson M, et al. . Senolytics reduce coronavirus-related mortality in old mice. Science (2021) 373:eabe4832. doi:&#xa0;10.1126/science.abe4832</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abe4832</ArticleId><ArticleId IdType="pmc">PMC8607935</ArticleId><ArticleId IdType="pubmed">34103349</ArticleId></ArticleIdList></Reference><Reference><Citation>Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol (1990) 28:1403&#x2013;10. doi:&#xa0;10.1128/jcm.28.6.1403-1410.1990</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jcm.28.6.1403-1410.1990</ArticleId><ArticleId IdType="pmc">PMC267940</ArticleId><ArticleId IdType="pubmed">2166084</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenu EW, van Driel ML, Staines DR, Ashton KJ, Ramos SB, Keane J, et al. . Immunological abnormalities as potential biomarkers in chronic fatigue Syndrome/Myalgic encephalomyelitis. J Transl Med (2011) 9:81. doi:&#xa0;10.1186/1479-5876-9-81</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-5876-9-81</ArticleId><ArticleId IdType="pmc">PMC3120691</ArticleId><ArticleId IdType="pubmed">21619669</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos S, Brenu E, Broadley S, Kwiatek R, Ng J, Nguyen T, et al. . Regulatory T, natural killer T and &#x3b3;&#x3b4; T cells in multiple sclerosis and chronic fatigue syndrome/myalgic encephalomyelitis: a comparison. Asian Pac J Allergy Immunol (2016) 34:300&#x2013;5. doi:&#xa0;10.12932/ap0733</Citation><ArticleIdList><ArticleId IdType="doi">10.12932/ap0733</ArticleId><ArticleId IdType="pubmed">27001659</ArticleId></ArticleIdList></Reference><Reference><Citation>Malato J, Sotzny F, Bauer S, Freitag H, Fonseca A, Grabowska AD, et al. . The SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) in myalgic encephalomyelitis/chronic fatigue syndrome: A meta-analysis of public DNA methylation and gene expression data. Heliyon (2021) 7:e07665. doi:&#xa0;10.1016/j.heliyon.2021.e07665</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2021.e07665</ArticleId><ArticleId IdType="pmc">PMC8320404</ArticleId><ArticleId IdType="pubmed">34341773</ArticleId></ArticleIdList></Reference><Reference><Citation>Ros&#xe9;n A, Gergely P, Jondal M, Klein G, Britton S. Polyclonal ig production after Epstein-Barr virus infection of human lymphocytes in vitro . Nature (1977) 267:52&#x2013;4. doi:&#xa0;10.1038/267052a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/267052a0</ArticleId><ArticleId IdType="pubmed">193041</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr JR. Epstein-Barr Virus (EBV) reactivation and therapeutic inhibitors. J Clin Pathol (2019) 72:651&#x2013;8. doi:&#xa0;10.1136/jclinpath-2019-205822</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jclinpath-2019-205822</ArticleId><ArticleId IdType="pubmed">31315893</ArticleId></ArticleIdList></Reference><Reference><Citation>Elfaitouri A, Herrmann B, Bolin-Wiener A, Wang Y, Gottfries CG, Zachrisson O, et al. . Epitopes of microbial and human heat shock protein 60 and their recognition in myalgic encephalomyelitis. PloS One (2013) 8:e81155. doi:&#xa0;10.1371/journal.pone.0081155</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0081155</ArticleId><ArticleId IdType="pmc">PMC3842916</ArticleId><ArticleId IdType="pubmed">24312270</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanz TV, Brewer RC, Ho PP, Moon JS, Jude KM, Fernandez D, et al. . Clonally expanded b cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature (2022) 603:321&#x2013;7. doi:&#xa0;10.1038/s41586-022-04432-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04432-7</ArticleId><ArticleId IdType="pmc">PMC9382663</ArticleId><ArticleId IdType="pubmed">35073561</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier UC, Cipian RC, Karimi A, Ramasamy R, Middeldorp JM. Cumulative roles for Epstein-Barr virus, human endogenous retroviruses, and human herpes virus-6 in driving an inflammatory cascade underlying MS pathogenesis. Front Immunol (2021) 12:757302. doi:&#xa0;10.3389/fimmu.2021.757302</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.757302</ArticleId><ArticleId IdType="pmc">PMC8592026</ArticleId><ArticleId IdType="pubmed">34790199</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox BS, Alharshawi K, Mena-Palomo I, Lafuse WP, Ariza ME. EBV/HHV-6A dUTPases contribute to myalgic Encephalomyelitis/Chronic-Fatigue-Syndrome pathophysiology by enhancing TFH cell differentiation and extrafollicular activities. JCI Insight (2022) 7:e158193. doi:&#xa0;10.1172/jci.insight.158193</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.158193</ArticleId><ArticleId IdType="pmc">PMC9220958</ArticleId><ArticleId IdType="pubmed">35482424</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato W, Ono H, Matsutani T, Nakamura M, Shin I, Amano K, et al. . Skewing of the b cell receptor repertoire in myalgic encephalomyelitis/chronic fatigue syndrome. Brain Behav Immun (2021) 95:245&#x2013;55. doi:&#xa0;10.1016/j.bbi.2021.03.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.03.023</ArticleId><ArticleId IdType="pubmed">33794313</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Montojo M, Doucet-O'Hare T, Henderson L, Nath A. Human endogenous retrovirus-K (HML-2): a comprehensive review. Crit Rev Microbiol (2018) 44:715&#x2013;38. doi:&#xa0;10.1080/1040841X.2018.1501345</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1040841X.2018.1501345</ArticleId><ArticleId IdType="pmc">PMC6342650</ArticleId><ArticleId IdType="pubmed">30318978</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Shehawi AM, Alotaibi SS, Elseehy MM. Genomic study of COVID-19 corona virus excludes its origin from recombination or characterized biological sources and suggests a role for HERVS in its wide range symptoms. Cytol Genet (2020) 54:588&#x2013;604. doi:&#xa0;10.3103/s0095452720060031</Citation><ArticleIdList><ArticleId IdType="doi">10.3103/s0095452720060031</ArticleId><ArticleId IdType="pmc">PMC7810191</ArticleId><ArticleId IdType="pubmed">33487779</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues LS, da Silva Nali LH, Leal COD, Sabino EC, Lacerda EM, Kingdon CC, et al. . HERV-K and HERV-W transcriptional activity in myalgic encephalomyelitis/chronic fatigue syndrome. Auto Immun Highlights (2019) 10:12. doi:&#xa0;10.1186/s13317-019-0122-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13317-019-0122-8</ArticleId><ArticleId IdType="pmc">PMC7065355</ArticleId><ArticleId IdType="pubmed">32257068</ArticleId></ArticleIdList></Reference><Reference><Citation>Trivedi MS, Oltra E, Sarria L, Rose N, Beljanski V, Fletcher MA, et al. . Identification of myalgic Encephalomyelitis/Chronic fatigue syndrome-associated DNA methylation patterns. PloS One (2018) 13:e0201066. doi:&#xa0;10.1371/journal.pone.0201066</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0201066</ArticleId><ArticleId IdType="pmc">PMC6056050</ArticleId><ArticleId IdType="pubmed">30036399</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawoko A, Johansson B, Rabinayaran D, Pipkorn R, Blomberg J. Increased immunoglobulin G, but not m, binding to endogenous retroviral antigens in HIV-1 infected persons. J Med Virol (2000) 62:435&#x2013;44. doi:&#xa0;10.1002/1096-9071(200012)62:4&lt;435::aid-jmv7&gt;3.0.co;2-r</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1096-9071(200012)62:4&lt;435::aid-jmv7&gt;3.0.co;2-r</ArticleId><ArticleId IdType="pubmed">11074471</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey TR, Akinyemi IA, Burton EM, Bhaduri-McIntosh S, McIntosh MT. An ancestral retrovirus envelope protein regulates persistent gammaherpesvirus lifecycles. Front Microbiol (2021) 12:708404. doi:&#xa0;10.3389/fmicb.2021.708404</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.708404</ArticleId><ArticleId IdType="pmc">PMC8381357</ArticleId><ArticleId IdType="pubmed">34434177</ArticleId></ArticleIdList></Reference><Reference><Citation>Musialik J, Kolonko A, Wiecek A. Increased EBV DNAemia after anti-SARS-CoV-2 vaccination in solid organ transplants. Vaccines (Basel) (2022) 10:992. doi:&#xa0;10.3390/vaccines10070992</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10070992</ArticleId><ArticleId IdType="pmc">PMC9325163</ArticleId><ArticleId IdType="pubmed">35891156</ArticleId></ArticleIdList></Reference><Reference><Citation>Grinde B. Herpesviruses: latency and reactivation - viral strategies and host response. J Oral Microbiol (2013) 5:22766&#x2013;75. doi:&#xa0;10.3402/jom.v5i0.22766</Citation><ArticleIdList><ArticleId IdType="doi">10.3402/jom.v5i0.22766</ArticleId><ArticleId IdType="pmc">PMC3809354</ArticleId><ArticleId IdType="pubmed">24167660</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia C, Nilsson J, Zurbuchen Y, Valaperti A, Schreiner J, Wolfensberger A, et al. . Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. J Allergy Clin Immunol (2021) 147:545&#x2013;57.e9. doi:&#xa0;10.1016/j.jaci.2020.10.040</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.10.040</ArticleId><ArticleId IdType="pmc">PMC7677074</ArticleId><ArticleId IdType="pubmed">33221383</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang N, P&#xe9;rez P, Kato T, Mikami Y, Okuda K, Gilmore RC, et al. . SARS-CoV-2 infection of the oral cavity and saliva. Nat Med (2021) 27:892&#x2013;903. doi:&#xa0;10.1038/s41591-021-01296-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01296-8</ArticleId><ArticleId IdType="pmc">PMC8240394</ArticleId><ArticleId IdType="pubmed">33767405</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkharaan H, Bayati S, Hellstr&#xf6;m C, Aleman S, Olsson A, Lindahl K, et al. . Persisting salivary IgG against SARS-CoV-2 at 9 months after mild COVID-19: A complementary approach to population surveys. J Infect Dis (2021) 224:407&#x2013;14. doi:&#xa0;10.1093/infdis/jiab256</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab256</ArticleId><ArticleId IdType="pmc">PMC8244549</ArticleId><ArticleId IdType="pubmed">33978762</ArticleId></ArticleIdList></Reference><Reference><Citation>Estevez-Lopez F, Castro-Marrero J, Wang X, Bakken IJ, Ivanovs A, Nacul L, et al. . Prevalence and incidence of myalgic encephalomyelitis/chronic fatigue syndrome in Europe-the Euro-epiME study from the European network EUROMENE: a protocol for a systematic review. BMJ Open (2018) 8:e020817. doi:&#xa0;10.1136/bmjopen-2017-020817</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2017-020817</ArticleId><ArticleId IdType="pmc">PMC6129044</ArticleId><ArticleId IdType="pubmed">30181183</ArticleId></ArticleIdList></Reference><Reference><Citation>Nacul L, Authier FJ, Scheibenbogen C, Lorusso L, Helland IB, Martin JA, et al. . European Network on myalgic Encephalomyelitis/Chronic fatigue syndrome (EUROMENE): Expert consensus on the diagnosis, service provision, and care of people with ME/CFS in Europe. Medicina (Kaunas) (2021) 57:510. doi:&#xa0;10.3390/medicina57050510</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina57050510</ArticleId><ArticleId IdType="pmc">PMC8161074</ArticleId><ArticleId IdType="pubmed">34069603</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Krieger AM, Yekutieli D. Adaptive linear step-up procedures that control the false discovery rate. Biometrika (2006) 93:491&#x2013;507. doi: 10.1093/biomet/93.3.491</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/93.3.491</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>